Vicki Morrison, M.D.

VA Medical Center

Vicki A. Morrison, M.D. is an Associate Professor of Medicine in the Sections of Hematology/Oncology and Infectious Disease.  Dr. Morrison received her infectious disease training at the National Naval Medical Center (Bethesda, MD), followed by Medical Oncology training at the University of Minnesota Hospital.  Her current clinical research interests include:  1) infectious complications of oncology patients, to include a) infectious complications of patients treated with nucleoside analogues,  b) mucosal immune function in patients with CLL and multiple myeloma,  c) neutropenic prophylaxis in patients receiving cyclical myelosuppressive therapy, d) therapeutic protocols utilizing echinocandins for fungal infections, and e) fungal infections in bone marrow transplant patients; 2) transplant-related lymphoproliferative disorders (evaluation, therapy), 3) therapy of intermediate-grade non-Hodgkin's lymphoma in the elderly, and 4) therapy and complications of chronic lymphocytic leukemia.

Selected Publications

Morrison VA, Weisdorf DJ.  The spectrum of Malassezia infections in the bone marrow transplant population.  Bone Marrow Transplant 2000; 26:645-648.

Morrison VA, Raj KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA.  Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.  J Clin Oncol 2001; 19:3611-3621.

Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgada DJ, Fridman M, Carter WB.  Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin’s lmphoma.  Oncology 2001; 15:1296-1306.

Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB.  The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: A risk factor analysis.  Clin Lymphoma 2001; 2:47-56.

Jahagirdar BN, Morrison VA.  Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients.  Semin Respir Infect 2002; 17:113-120.

Martell RE, Peterson BL, Cohen HJ, Petros WP, Raj KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.  Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia:  A CALGB (9011) coordinated interegroup study.  Cancer Chemother Pharmacol 2002; 50:37-45.

Morrison VA.  Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia.  Expert Rev Anticancer Ther 2001; 1:84-90.

Morrison VA, Raj KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA.  Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an intergroup study, cancer and leukemia group B 9011.  J Clin Oncol 2002; 20:3878-3884.

Cerosaletti KM, Morrison VA, Sabath DE, Willerford DM, Concannon P.  Mutatons and molecular variants of the NBS1 gene in non-Hodgkin’s lymphoma.  Genes Chromosomes Cancer 2002; 35:282-286.

Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Raj K, Schiffer CA, Larson RA.  Randomized phase 2 study of fludaabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712).  Blood 2003; 101: 6-14.

Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53.

Morrison VA. Caspofungin: an overview.  Expert Rev Anti Infect Ther 2005; 3:697-705 (Review).

Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.  Cancer 2005; 104:1661-7 (Review).

Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33:240-9 (Review).

Morrison V. Myeloid growth factors: to use or not to use, that is the question.  Leuk Lymphoma 2006; 47:780-2.

Morrison VA. Echinocandin antifungals: review and update.  Expert Rev Anti Infect Ther 2006; 4:325-42 (Review).